Tufts Medical Center

Running trials

• Not yet recruiting

  Brain and Obesity Longitudinal Development: Neurobiological Mechanisms of Semaglutide Treatment of Adolescent Obesity

  NCT07911046· Erin Mauney· Source

• Recruiting

  PrEcision Pacing in HFpEF: the PEP-HFpEF Trial

  NCT07864558· Tufts Medical Center· Source

• Recruiting

  Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

  NCT06917911· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer

  NCT07718854· Phase 2· Tufts Medical Center· Source

• Recruiting

  A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  NCT07623161· Phase 3· Takeda· Source

• Not yet recruiting

  Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis

  NCT06016517· Tufts Medical Center· Source

• Not yet recruiting

  Promoting Physical Activity Among Young Children With Autism

  NCT07747129· Northeastern University· Source

• Recruiting

  Vitamin D and Type 2 Diabetes - Treat-To-Target

  NCT07448974· Phase 3· Tufts Medical Center· Source

• Recruiting

  HCMR Re-Imaging Study

  NCT07054073· Christopher Kramer· Source

• Recruiting

  Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

  NCT07621809· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  ANDREAS Registry (Assessment of Novel Drug-coated Balloon Revascularization: Effectiveness, Angiographic Outcomes, and Safety)

  NCT07559903· Emory University· Source

• Recruiting

  Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

  NCT07215910· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07518186· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)

  NCT07318597· Phase 2· Regeneron Pharmaceuticals· Source

• Recruiting

  Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure

  NCT07232030· CVRx, Inc.· Source

• Recruiting

  An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

  NCT07365332· Phase 3· Inhibikase Therapeutics· Source

• Recruiting

  The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms

  NCT07143019· phenox Inc.· Source

• Recruiting

  Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

  NCT07404865· Phase 3· Vor Biopharma· Source

• Active, not recruiting

  Intravascular Neuro OCT Imaging System for Aneurysm Treatment Evaluation

  NCT07214220· Spryte Medical· Source

• Recruiting

  Pulmonary Embolism and Right-to-Left Shunts

  NCT07519876· Tufts Medical Center· Source

• Recruiting

  A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  NCT07188558· Phase 3· Lyell Immunopharma, Inc.· Source

• Recruiting

  Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

  NCT07061964· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

  NCT07161037· Phase 2· Vertex Pharmaceuticals Incorporated· Source

• Enrolling by invitation

  A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)

  NCT07156578· Phase 2· Rhythm Pharmaceuticals, Inc.· Source

• Recruiting

  Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

  NCT06769126· Phase 2· SWOG Cancer Research Network· Source

• Recruiting

  Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

  NCT07061977· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels

  NCT06939751· Northwestern University· Source

• Recruiting

  Early Feasibility Study (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study

  NCT07172464· Recross Cardio, Inc.· Source

• Recruiting

  An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07184996· Phase 3· Sanofi· Source

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  NCT07184931· Phase 3· Sanofi· Source

• Recruiting

  Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  NCT06982521· Phase 3· Relay Therapeutics, Inc.· Source

• Recruiting

  ELEVATE-HFpEF Clinical Study

  NCT06678841· Medtronic Cardiac Rhythm and Heart Failure· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

  NCT06944522· Phase 3· BlueRock Therapeutics· Source

• Recruiting

  Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

  NCT06577441· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

  NCT06902558· Phase 2· Calico Life Sciences LLC· Source

• Recruiting

  A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

  NCT06952504· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  NCT06672146· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

  NCT06934226· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

  NCT06873945· Phase 3· Pfizer· Source

• Recruiting

  Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

  NCT06661720· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Alleviant ALLAY-HFrEF Study

  NCT06812533· Alleviant Medical, Inc.· Source

• Recruiting

  Myo-inositol During Pregnancy to Prevent Gestational Diabetes

  NCT06575868· Tufts Medical Center· Source

• Recruiting

  Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  NCT06731478· Phase 3· Daiichi Sankyo· Source

• Recruiting

  Family-Based Weight Wellness Treatment Through Food is Medicine and Group Medical Visits in Pediatric and Adult Primary Care

  NCT07717658· Tufts University· Source

• Active, not recruiting

  EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

  NCT06556563· Phase 3· NovoCure GmbH· Source

• Recruiting

  Remote Tai Chi for Knee Osteoarthritis

  NCT06384898· Tufts Medical Center· Source

• Active, not recruiting

  Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease

  NCT06747572· Vertex Pharmaceuticals Incorporated· Source

• Recruiting

  Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

  NCT06736574· Phase 3· Cytokinetics· Source

• Active, not recruiting

  Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

  NCT06632327· Phase 3· Alliance for Clinical Trials in Oncology· Source

Showing 50 of 196.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure12 recruiting
• Acute myeloid leukaemia7 recruiting
• Childhood cancers5 recruiting
• Multiple myeloma5 recruiting
• Ovarian cancer5 recruiting
• Stroke5 recruiting
• Amyloidosis4 recruiting
• High blood pressure4 recruiting
• Obesity4 recruiting
• Pulmonary arterial hypertension4 recruiting
• Bladder cancer3 recruiting
• Chronic lymphocytic leukaemia3 recruiting
• Coronary artery disease3 recruiting
• Head and neck cancer3 recruiting
• Lung cancer3 recruiting
• Myelodysplastic syndromes3 recruiting
• Myeloproliferative neoplasms3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Atrial fibrillation2 recruiting
• Cervical cancer2 recruiting
• Colorectal cancer2 recruiting
• Endometrial cancer2 recruiting
• Gastric and oesophageal cancer2 recruiting
• Hypertrophic cardiomyopathy2 recruiting
• Idiopathic pulmonary fibrosis2 recruiting
• Kidney cancer2 recruiting
• Metastatic breast cancer2 recruiting
• Rheumatoid arthritis2 recruiting
• Sjögren's disease2 recruiting
• Triple-negative breast cancer2 recruiting
• Alzheimer disease1 recruiting
• Aortic aneurysm1 recruiting
• Aortic stenosis1 recruiting
• Aplastic anaemia1 recruiting
• Autism1 recruiting
• Brain aneurysm1 recruiting
• Chronic kidney disease1 recruiting
• Chronic myeloid leukaemia1 recruiting
• COPD1 recruiting
• Crohn's disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Glioblastoma1 recruiting
• Hodgkin lymphoma1 recruiting
• Liver and biliary tract cancer1 recruiting
• Lupus (SLE)1 recruiting
• Melanoma1 recruiting
• Meningioma1 recruiting
• Osteoarthritis1 recruiting
• Parkinson disease1 recruiting
• Peripheral artery disease1 recruiting
• Polycystic kidney disease1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Sarcoidosis1 recruiting
• Schizophrenia1 recruiting
• Thyroid cancer1 recruiting
• Type 2 diabetes1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Recruiting

  Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

  NCT06846281· Phase 3· Novartis Pharmaceuticals· Source

• Withdrawn

  Using WHOOP Fitness Band to Measure Heart Health Variability Before and After Surgery

  NCT07097168· Tufts Medical Center· Source

• Terminated

  Comparative Effectiveness of Prophylactic ICD Versus Non-ICD Therapy

  NCT06543446· University of Rochester· Source

• Terminated

  Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

  NCT05554354· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  RECOVER-SLEEP: Platform Protocol

  NCT06404086· Phase 2· Duke University· Source

• Recruiting

  Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

  NCT06282575· Phase 3· Jazz Pharmaceuticals· Source

• Completed

  RECOVER-ENERGIZE Platform Protocol

  NCT06404047· Duke University· Source

• Completed

  A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity

  NCT06046443· Phase 2· Rhythm Pharmaceuticals, Inc.· Source

• Withdrawn

  Study of ADI CardioPulmonary Management (CPM) System

  NCT06024369· Analog Device, Inc.· Source

• Completed

  Pilot: Intraoperative TAP Block and Post-operative Pain Control for Minimally Invasive Hysterectomy for Endometrial Cancer

  NCT05763667· Phase 3· Tufts Medical Center· Source

• Completed

  Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

  NCT05934526· Phase 3· GB002, Inc.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)

  NCT06181435· Phase 3· Sanofi· Source

• Completed

  Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria

  NCT06150924· Phase 2· Mineralys Therapeutics Inc.· Source

• Completed

  RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms

  NCT05595369· Phase 2· Kanecia Obie Zimmerman· Source

• Completed

  Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

  NCT05834738· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Boehringer Ingelheim· Source

• Completed

  Mind-body Approach and Gut Microbiota in Osteoarthritis

  NCT05186714· Tufts Medical Center· Source

• Completed

  A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease

  NCT05521191· Phase 1· Regulus Therapeutics Inc.· Source

• Completed

  Development and Evaluation of "Period Kits" for Adolescents With Intellectual and Developmental Disabilities

  NCT05497167· Tufts Medical Center· Source

• Completed

  A Pragmatic Approach to Lower Diabetes Risk After Gestational Diabetes

  NCT05280496· Phase 3· Tufts Medical Center· Source

• Completed

  Apple Watch Heart Failure Study

  NCT04510779· Tufts Medical Center· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo

  NCT05247489· Phase 2· Incyte Corporation· Source

• Completed

  Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor

  NCT05216250· Phase 2· AbbVie· Source

• Terminated

  Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients

  NCT05251727· Phase 1· Asahi Kasei Therapeutics, Inc.· Source

• Completed

  Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

  NCT03941860· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Letermovir Use in Heart Transplant Recipients

  NCT04904614· Phase 4· Tufts Medical Center· Source

• Terminated

  A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy

  NCT04856176· Phase 2· Tufts Medical Center· Source

• Completed

  A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

  NCT04945460· Phase 2· Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA· Source

• Completed

  A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)

  NCT04896008· Phase 3· Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA· Source

• Completed

  Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)

  NCT05172024· NYU Langone Health· Source

• Completed

  Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

  NCT05024045· Phase 1· Eli Lilly and Company· Source

• Terminated

  Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

  NCT04588246· Phase 3· NRG Oncology· Source

• Completed

  Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

  NCT04708782· Phase 3· United Therapeutics· Source

• Completed

  A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT04777201· Phase 3· Hoffmann-La Roche· Source

• Completed

  Food As Medicine for Heart Failure

  NCT04847973· Tufts Medical Center· Source

• Terminated

  Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

  NCT04816604· Phase 2· Gossamer Bio USA, Inc.· Source

• Completed

  An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD

  NCT04770545· Phase 3· Apellis Pharmaceuticals, Inc.· Source

• Completed

  Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee

  NCT04636229· Phase 3· Organogenesis· Source

• Completed

  Evaluation of AMG 714 for Vitiligo

  NCT04338581· Phase 2· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Completed

  Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

  NCT04471844· NovoCure Ltd.· Source

• Completed

  A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke

  NCT04309474· Phase 2· AbbVie· Source

• Recruiting

  NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness

  NCT04471909· Endospan Ltd.· Source

• Completed

  The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock

  NCT04325035· Phase 2· Windtree Therapeutics· Source

• Completed

  Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

  NCT04411641· Phase 3· Sanofi· Source

• Completed

  SURPASS Impella 5.5 Study

  NCT05100836· Abiomed Inc.· Source

• Completed

  Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)

  NCT04295538· Phase 2· AbbVie· Source

• Completed

  Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

  NCT04458051· Phase 3· Sanofi· Source

• Terminated

  A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

  NCT04271475· Phase 3· Actelion· Source

• Completed

  Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

  NCT04374630· Phase 2· Laekna Limited· Source

Showing 50 of 87.

Conditions

Diseases this institution publishes on or runs trials for.

• Heart failure102 works · 27 trials
• Amyloidosis16 works · 8 trials
• Pulmonary arterial hypertension15 works · 12 trials
• Brain aneurysm6 works · 3 trials
• Polycystic kidney disease6 works · 4 trials
• Cushing's syndrome3 works · 0 trials